No association between a common type 2 diabetes risk gene variant in the melatonin receptor gene (MTNR1B) and mortality among type 2 diabetes patients

Xue, Ping; Tan, Xiao; Wu, Jiafei; Tang, Xiangdong

doi:10.1111/jpi.12785

Cited by 3 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, although the frequency of the CTT haplotype was significantly different between the MI patient group and the control group in the present study, this difference was no longer significant after correction for multiple testing. Similarly, a study by Xue et al showed that MTNR1B gene variations in patients with diabetes did not increase their risk of CVD mortality [12]. In addition, some of the analyzed cardiovascular risk factors, such as diastolic and systolic blood pressure, BMI, and smoking, were significantly associated with the analyzed polymorphisms in MI patients in this study.…”

Section: Discussionsupporting

confidence: 78%

“…Melatonin action involves the activation of a high-affinity membrane receptor, melatonin receptor 1B [3], encoded by the MTNR1B gene [12].…”

Section: Introductionmentioning

confidence: 99%

“…Diabetic complications are highly prevalent and may facilitate atherosclerosis and plaque progression, consequently leading to harmful coronary events [17,18]. Myocardial infarction (MI), one of CVD's most important diagnostic subgroups, is the major cause of death in diabetic patients [12,17]. Numerous studies confirmed the association between MTNR1B gene polymorphisms and the risk of type 2 diabetes [2,6,15,19,20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Myocardial Infarction Susceptibility and the MTNR1B Polymorphisms

Škrlec

Biloglav

Talapko

et al. 2023

IJMS

View full text Add to dashboard Cite

Melatonin is a circadian hormone with antioxidant properties that protects against myocardial ischemia-reperfusion injury. Genetic variations of the melatonin receptor 1B gene (MTNR1B) play an important role in the development of type 2 diabetes, a risk factor for cardiovascular diseases. Accordingly, MTNR1B polymorphisms are crucial in numerous disorders of the cardiovascular system. Therefore, the aim of the present study was to investigate a possible association of MTNR1B polymorphisms with chronotype and susceptibility to myocardial infarction. The present case-control study included 199 patients with myocardial infarction (MI) (57% men) and 198 control participants (52% men) without previous cardiovascular diseases who underwent genotyping for the MTNR1B polymorphisms rs10830963, rs1387153, and rs4753426 from peripheral blood samples. Chronotype was determined using the Morningness-Eveningness Questionnaire (MEQ). As estimated by the chi-square test, no significant association was found in the distribution of alleles and genotypes between myocardial infarction patients and controls. In addition, there was no association between MTNR1B polymorphisms and chronotype in MI patients. As some previous studies have shown, the present negative results do not exclude the role of the MTNR1B polymorphisms studied in the development of myocardial infarction. Rather, they may indicate that MTNR1B polymorphisms are a minor risk factor for myocardial infarction.

show abstract

Section: Discussionsupporting

confidence: 78%

“…Melatonin action involves the activation of a high-affinity membrane receptor, melatonin receptor 1B [3], encoded by the MTNR1B gene [12].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Myocardial Infarction Susceptibility and the MTNR1B Polymorphisms

Škrlec

Biloglav

Talapko

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Seventh, we excluded events that occurred within one year of follow-up. In addition, we performed analyses by censoring up to 31 Dec 2019 (the start of the COVID-19 pandemic 47 ). Finally, we repeated the analyses among those with ≥6 days of accelerometer wear.…”

Section: Methodsmentioning

confidence: 99%

Associations of timing of physical activity with all-cause and cause-specific mortality in a prospective cohort study

Feng

Liang

et al. 2023

Nat Commun

Self Cite

View full text Add to dashboard Cite

There is a growing interest in the role of timing of daily behaviors in improving health. However, little is known about the optimal timing of physical activity to maximize health benefits. We perform a cohort study of 92,139 UK Biobank participants with valid accelerometer data and all-cause and cause-specific mortality outcomes, comprising over 7 years of median follow-up (638,825 person-years). Moderate-to-vigorous intensity physical activity (MVPA) at any time of day is associated with lower risks for all-cause, cardiovascular disease, and cancer mortality. In addition, compared with morning group (>50% of daily MVPA during 05:00-11:00), midday-afternoon (11:00-17:00) and mixed MVPA timing groups, but not evening group (17:00-24:00), have lower risks of all-cause and cardiovascular disease mortality. These protective associations are more pronounced among the elderly, males, less physically active participants, or those with preexisting cardiovascular diseases. Here, we show that MVPA timing may have the potential to improve public health.

show abstract

“…Regarding clinical endpoints, individuals with T2DM possessing the MTNR1B gene variant had a greater incidence of myocardial infarction in an analysis of the UK Biobank cohort with a 6.8-year follow-up [64]. In contrast, no associations with mortality have been found [65].…”

Section: Mt and Glucose Homeostasismentioning

confidence: 99%

The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal?

Theofilis

Vordoni

Kalaitzidis³

2022

Am J Nephrol

View full text Add to dashboard Cite

Background: The increasing incidence of chronic kidney disease (CKD), as a consequence of the high prevalence of arterial hypertension and type 2 diabetes mellitus (T2DM), warrants the need for developing effective treatment approaches. In this regard, the pineal gland-derived hormone melatonin may represent an appealing treatment approach of CKD and its associated risk factors. Summary: Targeting the adverse pathophysiology surrounding CKD and its associated risk factors has been the concept of pharmacologic treatment developed for its management. This review article aimed to present the role of melatonin in this direction, by providing an overview of melatonin’s physiology followed by its effect as a therapeutic agent in arterial hypertension and T2DM. Key Messages: Melatonin, the primary darkness hormone, possesses pleiotropic mechanisms of action which may have important implications in various pathologic states since its receptors are situated across various organ systems. As a treatment tool in arterial hypertension, melatonin may be efficacious in reducing both daytime and nocturnal blood pressure by influencing endothelial function, oxidative stress, the autonomic nervous system, and the renin-angiotensin system. Melatonin may also increase insulin sensitivity and β-cell function. However, late meal intake may be detrimental in glucose regulation, as consumption close to melatonin peak concentrations may induce hyperglycemia and insulin resistance. This finding may explain the inconsistent glycose regulation achieved with melatonin in clinical trials and meta-analyses. Additionally, the presence of genetic variants to melatonin receptor 2 may predispose to T2DM development. Finally, we present the available preclinical evidence supporting melatonin’s efficacy in ameliorating CKD’s pathophysiology since melatonin supplementation has not been adequately explored in patients with CKD. The combined use of stem cells with melatonin is an appealing therapeutic approach which ought to be assessed further.

show abstract

No association between a common type 2 diabetes risk gene variant in the melatonin receptor gene (MTNR1B) and mortality among type 2 diabetes patients

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 3 publications

References 23 publications

Myocardial Infarction Susceptibility and the MTNR1B Polymorphisms

Myocardial Infarction Susceptibility and the MTNR1B Polymorphisms

Associations of timing of physical activity with all-cause and cause-specific mortality in a prospective cohort study

The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal?

Contact Info

Product

Resources

About